Cellectis (NASDAQ:CLLS) was upgraded by investment analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued to clients and investors on Saturday, February 17th.
Other equities analysts have also recently issued research reports about the stock. Zacks Investment Research cut shares of Cellectis from a “buy” rating to a “hold” rating in a research report on Thursday, November 16th. ValuEngine upgraded shares of Cellectis from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Oppenheimer restated an “outperform” rating and issued a $40.00 target price on shares of Cellectis in a report on Thursday, December 28th. Finally, Jefferies Group restated a “buy” rating and issued a $47.00 target price on shares of Cellectis in a report on Sunday, October 29th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $42.67.
Shares of Cellectis (CLLS) traded up $3.54 on Friday, reaching $35.19. 735,188 shares of the company’s stock were exchanged, compared to its average volume of 140,521. The company has a market capitalization of $1,280.00 and a PE ratio of -12.52. Cellectis has a twelve month low of $21.25 and a twelve month high of $36.13.
ILLEGAL ACTIVITY WARNING: “Cellectis (CLLS) Upgraded to Strong-Buy by BidaskClub” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://stocknewstimes.com/2018/03/14/cellectis-clls-rating-increased-to-strong-buy-at-bidaskclub-2.html.
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.